Natera, Inc.
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Signatera Clinical Average Selling Price by Quarter
Signatera Clinical Average Selling Price — Realized ASP ($/test) ($)
Natera Signatera Clinical Average Selling Price: $1,275 in Q2 2026, up 8.5% from a year earlier.
Where the Q2 2026 figure comes from
“Signatera Average Selling Price (ASP) -- approximately $1,275, reflecting increased reimbursement from Medicare Advantage and commercial plans in biomarker states.”
Source: Q2 2026 Earnings Call Transcript ↗
Realized average selling price (ASP) per Signatera clinical MRD test (~$1,165 in Q2 2025; ~$1,200 in Q3 2025; ~$1,225 in Q4 2025; ~$1,290 in Q1 2026; ~$1,300 in Q2 2026).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Signatera Clinical Average Selling Price — Realized ASP ($/test) ($) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,275 | +8.5% | Q2 2026 Earnings Call Transcript ↗ |
| Q1 2026 | Mar 31, 2026 | 1,250 | – | Q1 2026 Earnings Call Transcript ↗ |
| Q4 2025 | Dec 31, 2025 | 1,225 | – | Q4 2025 Earnings Call Transcript ↗ |
| Q3 2025 | Sep 30, 2025 | 1,200 | – | Q3 2025 Earnings Call Transcript ↗ |
| Q2 2025 | Jun 30, 2025 | 1,175 | – | Q2 2025 Earnings Call Transcript ↗ |
Cite this data
StockData. (2026). Natera Signatera Clinical Average Selling Price ($), quarterly Q2 2025–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/asp-signatera
See every metric in the Natera KPI table. Data updated Nov 2, 2026.